GnRH analogs: Options for endometriosis-associated pain treatment
review
OA: closed
CC0
⤵ 33 in-corpus citations
AI-generated summary
This review discusses gonadotropin-releasing hormone (GnRH) analogs as therapeutic options for endometriosis-associated pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
While none of the currently available treatment options for endometriosis pain resolved the underlying disease process, there are growing numbers of medical alternatives available. Medical options include the GnRH agonists and antagonists. Review of these treatments in the management of endometriosis pain and the insight often to the etiology of endometriosis are presented for discussion.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (77)
- ACOG Committee Opinion #310: Endometriosis in Adolescents via openalex
- A comparison of nafarelin acetate and danazol in the treatment of endometriosis via openalex
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin via openalex
- Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study via openalex
- Buserelin versus danazol in the treatment of endometriosis-associated infertility via openalex
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis via openalex
- Effect of GnRH analogues on apoptosis and release of interleukin-1 and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis via openalex
- Effects of Triptorelin Versus Placebo on the Symptoms of Endometriosis via openalex
- Endometriosis in Adolescents via openalex
- GnRH II as a possible cytostatic regulator in the development of endometriosis via openalex
- Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas via openalex
- Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis via openalex
- Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary via openalex
- Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial via openalex
- Gonadotropin-releasing hormone agonist treatment reduced serum interleukin-6 concentrations in patients with ovarian endometriomas via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density? via openalex
- Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1 via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study via openalex
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up via openalex
- Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study via openalex
- Medical management of endometriosis and infertility via openalex
- Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
- Nafarelin for endometriosis: A large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
- Nafarelin in the treatment of pelvic pain caused by endometriosis via openalex
- Nafarelin versus danazol in the treatment of endometriosis via openalex
- Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. via openalex
- One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial via openalex
- Pain of endometriosis: effects of nafarelin and danazol therapy. via openalex
- Peritoneal Cellular Immunity and Endometriosis via openalex
- Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis via openalex
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 via openalex
- Prolonged gonadotropin-releasing hormone agonist therapy reduced expression of nitric oxide synthase in the endometrium of women with endometriosis and infertility via openalex
- Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy via openalex
- Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: A double-blind, randomized, placebo-controlled trial via openalex
- Quantitative analysis of estrogen receptor alpha and beta messenger ribonucleic acid levels in normal endometrium and ovarian endometriotic cysts using a real-time reverse transcription-polymerase chain reaction assay via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. via openalex
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
- Should add-back therapy for endometriosis be deferred for optimal results? via openalex
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment via openalex
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. via openalex
- The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- The effects of combining norethindrone with a gonadotropin‐releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- The efficacy of drugs in the management of endometriosis via openalex
- The Use of GnRH Agonists in the Medical Therapy of Endometriosis in the Woman with Pain via openalex
- Treatment options in endometriosis. via openalex
- Use of GnRH antagonists in the treatment of endometriosis via openalex
- Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis via openalex
- Validation study of nonsurgical diagnosis of endometriosis via openalex
- Vascular endothelial growth factor and endometriotic angiogenesis via openalex
- Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. via openalex
- W2140246703 via openalex
- W2412382222 via openalex
- W2126729416 via openalex
- W2123876576 via openalex
- W2108270037 via openalex
- W2417044776 via openalex
- W2100281208 via openalex
- W2093303434 via openalex
- W2077563872 via openalex
- W2068643120 via openalex
- W2028587418 via openalex
- W3022929224 via openalex
- W1989585204 via openalex
- W110566743 via openalex
- W6655287665 via openalex
- W6672127118 via openalex
- W6715235543 via openalex
- W6717426660 via openalex
- W2347177325 via openalex
- W6777152678 via openalex
- W2399999566 via openalex
- W2401134385 via openalex
- W2172273432 via openalex
Cited by (33)
- Esketamine infusion therapy: A promising alternative in the treatment of chronic endometriosis-associated pain 2024
- Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysis 2021
- Perbandingan Skala Nyeri Pasien Kista Endometriosis Dan Adenomiosis Sebelum Operasi, Setelah Operasi Dan Setelah Pemberian GNRH Analog 2020
- Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis 2020
- Perbandingan Skala Nyeri Pasien Kista Endometriosis Dan Adenomiosis Sebelum Operasi, Setelah Operasi Dan Setelah Pemberian GNRH Analog 2020
- Perbandingan Skala Nyeri Pasien Kista Endometriosis Dan Adenomiosis Sebelum Operasi, Setelah Operasi Dan Setelah Pemberian GNRH Analog 2020
- Effect of neuromuscular electrical stimulation for endometriosis-associated pain 2018
- Low-dose add-back therapy during postoperative GnRH agonist treatment 2016
- Minimising menopausal side effects whilst treating endometriosis and fibroids 2015
- Gonadotrophin‐releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi‐center randomized trial 2015
- Safety of medical treatments for endometriosis 2015
- Roles of regulatory T cells in endometriosis-associated infertility 2014
- Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density 2014
- Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study 2013
- Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women. 2013
- Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study 2013
- Possible involvement of nerve growth factor in dysmenorrhea and dyspareunia associated with endometriosis 2013
- Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis 2013
- Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update 2012
- Hormonal strategy for the primary or secondary treatment of endometriosis 2012
- Quality of life according to add-back therapy during GnRH agonist treatment in endometriosis patients 2012
- Innovations in conservative endometriosis treatment: an updated review. 2011
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment 2011
- Treatment of Endometriosis and Chronic Pelvic Pain with Letrozole and Norethindrone Acetate 2010
- Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? 2010
- Aromatase Inhibitors: Potential Reproductive Implications 2009
- Endometriosis 2009
- Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after conservative laparoscopic surgery 2008
- New drugs in development for the treatment of endometriosis 2008
- Treatment strategies for endometriosis 2008
- Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists 2008
- Inflammatory Status Influences Aromatase and Steroid Receptor Expression in Endometriosis 2007
- Control of chronic pelvic pain 2006
Source provenance
- europepmc
- last seen: 2026-08-23T09:30:01.253652+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:15:12.369988+00:00
- unpaywall
- last seen: 2026-08-23T06:29:45.520198+00:00
License: CC0
· commercial use OK